Frequently Asked Questions

Stem cell therapy for autism involves the administration of mesenchymal stem cells (MSCs), typically derived from umbilical cord tissue (Wharton's Jelly), to address biological factors associated with autism spectrum disorder. MSCs release anti-inflammatory molecules, growth factors, and exosomes that may help reduce neuroinflammation, modulate immune function, support gut health, and promote neural repair. It is an advanced intervention, not a cure.

UC-MSCs have a favorable safety profile documented in published studies. They are immunologically privileged and do not require donor matching. All our products undergo comprehensive testing for sterility, viability, potency, and genetic stability. As with any medical procedure, risks exist and are discussed thoroughly during consultation.

Results vary by individual. Some families report improvements in eye contact, language, social engagement, behavioral regulation, sleep, and GI function. We set realistic expectations and monitor progress systematically through our follow-up program. We never promise cures or guaranteed outcomes.

Stem cells are live cells that migrate to inflamed tissues and release therapeutic factors over time. Exosomes are concentrated nano-vesicles derived from stem cells that deliver rapid, targeted biological signals with superior blood-brain barrier penetration. We often combine both for comprehensive coverage.

We use mesenchymal stem cells derived from Wharton's Jelly (umbilical cord tissue), sourced from GMP-certified laboratories. These are ethically sourced from donated tissue following healthy births, extensively tested, and do not require donor-recipient matching.

Through intravenous (IV) infusion for systemic anti-inflammatory effects and/or intrathecal injection for direct CNS delivery. The optimal route is determined during your child's personalized treatment planning based on their specific clinical profile.

Yes. Some children benefit from additional sessions at intervals determined by response to initial treatment. Our follow-up monitoring program tracks progress and guides decisions about additional treatment.

Typically 5-7 days including initial assessments, treatment sessions, monitoring, and discharge consultation. Some families extend their stay for tourism or additional observation.

The cost of stem cell therapy for autism depends on the protocol — cell source, dose count, administration routes (IV, intrathecal, intranasal exosomes), and visit length. Stem cell therapy for autism in Istanbul, Turkey is typically 50–70% more affordable than equivalent regenerative medicine in the United States, United Kingdom or Western Europe, without compromising on GMP-certified cell quality. Families receive a transparent itemized quote during the free consultation.

Stem cell therapy for autism is offered in several countries — Turkey, Panama, Mexico, the United States (mainly in clinical-trial settings), and parts of Europe and Asia. Families increasingly choose Istanbul, Turkey because it combines internationally accredited clinics, GMP-certified umbilical cord MSC and exosome products, English-speaking medical coordination, direct flight access from most of the world, and significantly more competitive pricing than the US, UK or Western Europe — under formal medical oversight.

Stem cell therapy for autism is not currently FDA approved as a routine treatment in the United States; it is considered investigational there and is mainly available via registered clinical trials. Outside the US, regulated regenerative medicine clinics — including specialized centers in Istanbul, Turkey — provide MSC and exosome protocols under their own national medical frameworks. Autism Stem Care discusses regulatory context openly during consultation.

Yes. We welcome families from around the world with dedicated international patient support. Our team communicates fluently in English and assists with all aspects of medical travel to Istanbul, Turkey.

There is no rigid universal age limit for stem cell therapy for autism. Most international protocols are designed for children roughly 2 to 18 years old. Younger children often have greater neurodevelopmental plasticity, while older children and teenagers remain eligible when medically appropriate. Eligibility at Autism Stem Care depends on overall health, diagnostic profile and safety screening, reviewed individually.

There is no single official success rate for stem cell therapy in autism — outcomes are highly individual and depend on age, biology, baseline symptoms and protocol. Published research on umbilical cord MSCs for autism has reported encouraging signals in communication, behavior and inflammation, but it remains an investigational therapy worldwide. Families receive realistic expectations, not guaranteed outcomes.

Yes. Our structured follow-up program includes video consultations at 1, 3, 6, and 12 months post-treatment, standardized outcome tracking, and ongoing access to our team for questions and concerns.

We recommend bringing medical records, developmental assessments, recent lab work, a list of medications, comfort items for your child, sensory support items, entertainment for waiting periods, and travel documents.

Requirements vary by country. Many nationalities can enter visa-free or obtain an e-Visa online. Our team provides visa guidance specific to your country of origin.

Yes. Our coordination team provides hotel recommendations, booking assistance, VIP airport transfers, and arranges all ground transportation during your stay.

Absolutely. We strongly encourage continuing speech therapy, OT, ABA, and other interventions alongside regenerative medicine. Our approach is complementary, not a replacement for established therapies.

Eligibility is determined through our consultation process, which includes a review of medical history, developmental profile, current health status, and any contraindications. Not every child is a candidate — we evaluate honestly and will not recommend treatment if it is not appropriate.

The gut-brain axis is the bidirectional communication pathway between the intestinal tract and the central nervous system. Approximately 90% of the body's serotonin is produced in the gut, meaning gut health directly affects mood, behavior, and brain function. Disruption of this pathway is common in autism and is a key target of our treatment approach.

Neuroinflammation is chronic inflammation within the brain and central nervous system, driven by persistently activated microglial cells. This inflammatory state can impair neural development, disrupt connectivity, and affect neurotransmitter production — contributing to many autism symptoms. It is one of our primary treatment targets.